IA
NBIX icon

IFG Advisory’s Neurocrine Biosciences NBIX Stock Holding History

IFG Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Buy
+64
New +$9.49K ﹤0.01% 1820
2021
Q4 		– Sell
-2,506
Closed -$240K – 508
2021
Q3 		$240K Buy
2,506
+33
+1% +$3.12K 0.03% 433
2021
Q2 		$240K Buy
+2,473
New +$237K 0.03% 424
2020
Q4 		– Sell
-2,264
Closed -$217K – 455
2020
Q3 		$217K Buy
2,264
+35
+2% +$4.05K 0.04% 378
2020
Q2 		$271K Sell
2,229
-100
-4% -$11.1K 0.05% 323
2020
Q1 		$201K Sell
2,329
-2,278
-49% -$223K 0.04% 343
2019
Q4 		$495K Buy
+4,607
New +$482K 0.09% 236

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IFG Advisory's NBIX Position: Q2 2026 in Review

IFG Advisory opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 64 shares worth $10.8K. The stake represents ﹤0.01% of the portfolio and ranks #1820 among its holdings. This is a return to the name: IFG Advisory previously reported a position in NBIX as recently as Q3 2021.

IFG Advisory first reported a position in NBIX in Q4 2019 and has held it in 7 quarters since. The position peaked at $495K in Q4 2019. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • IFG Advisory held 64 shares of Neurocrine Biosciences worth $10.8K as of Q2 2026.
  • Neurocrine Biosciences was a new IFG Advisory position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #1820 holding.
  • IFG Advisory first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 7 quarters since.
  • IFG Advisory's Neurocrine Biosciences position peaked at $495K in Q4 2019.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.